ArticleDermatology and therapy2026
Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world evidence investigating treatment patterns and associated economic outcomes in patients with psoriasis (PsO) are lacking. This study evaluated treatment patterns, healthcare resource utilisation (HCRU), and costs in biologic-naïve patients with moderate-to-severe PsO initiating biologics in France.
methodsBiologic-naïve adults with moderate-to-severe PsO initiating an anti-tumour necrosis factor (TNFα) or anti-interleukin (IL) biologic were identified from the Système National des Données de Santé. Switching and dose escalation rates, calculated using Kaplan-Meier analyses, were assessed over 42 months of follow-up. HCRU and costs were assessed during the 12 months following initiation. Comparisons between switchers/non-switchers and dose escalators/non-dose escalators were conducted using Wilcoxon rank sum, chi-square, and Fisher exact tests.
resultsOverall, 20,995 biologic-naïve adult patients initiating a biologic were included in the analysis. At 42 months, switch rates and dose escalation rates were lowest for patients initiating anti-IL-23 agents and highest for anti-TNFα agents. Specifically, the lowest rate of switching (15.0%) and dose escalation (9.0%) were observed for patients treated with the anti-IL-23 agent risankizumab. The mean number of total healthcare visits at 12 months was significantly (p < 0.001) higher for treatment switchers versus non-switchers (48.8 vs 39.0) and dose escalators versus non-dose escalators (47.4 vs 39.9). Furthermore, switchers had significantly (p < 0.001) higher mean medical (€3435 vs €2578), inpatient (€1126 vs €826), outpatient (€1751 vs €1331), and pharmacy (€13,105 vs €10,589) costs versus non-switchers. Similar trends were observed for dose escalators versus non-dose escalators (€3453 vs €2638; €965 vs €870; €1682 vs €1371; and €13,736 vs €10,683, respectively, p < 0.001).
conclusionAnti-IL-23 agents demonstrated the lowest rates of switching and dose escalation over 42 months, whilst anti-TNFα agents had the highest rates. More specifically, the lowest rates were observed for patients treated with risankizumab. Overall, higher rates of switching or dose escalation corresponded with higher HCRU and costs.
Indexed as
Identifiers
42622792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.